FDA staff worries about risks of cancer, suicide in COPD drug Daxas

04/5/2010 | Reuters

FDA reviewers voiced concern about suicide and suicide attempts by clinical-trial patients who received Daxas, a drug for chronic obstructive pulmonary disease from Forest Laboratories and Nycomed. Forest said an analysis of the cases "does not suggest a causal relationship" with Daxas, which is also linked to a higher risk of cancer, according to FDA data.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX